Autogenomics

Federal prosecutors alleged AutoGenomics paid nursing home patients to get tested in exchange for being referred for testing.

Prescient will further the development and commercialization of the Infiniti Neural Response Panel to identify patients who may be at risk for opioid use disorder.

The designation will help the company accelerate the process of bringing the opioid addiction risk test through regulatory review and clearance.